Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question.
To evaluate the role of Stereotactic Body Radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer. Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression free survival (PFS) and overall survival (OS). From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). Local control at 1 and 2 years were 88.9% (95% CI 73.2-98.6) and 73.9% (95% CI 50-87.5), respectively. Median local control was 39.9 months (95% CI 23.3 - not reached).PFS rates at 1 and 2 years were 21.9% (95% CI 10.8 - 35.4) and 10.9% (95% CI 3.4 - 23.4), respectively. Median PFS was 5.4 months (95%CI 3.1 - 11.3).OS rates at 1 and 2 years were 79.9% (95% CI 63.7 - 89.4) and 46.7% (95% CI 29.6 - 62.2). Median OS was 23 months (95%CI 14.1 - 31.8). Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results. Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT.